HemaTox™髓系试剂盒

用于测定药物髓系造血毒性的无血清培养基及补充剂

只有 %1 左

率先评论此产品

¥16,496.00

产品号 #（选择产品）

产品号 #09704_C

用于测定药物髓系造血毒性的无血清培养基及补充剂

产品组分包括

HemaTox™髓系培养基，100 mL
HemaTox™髓系100X补充剂，1 mL

立即询价

总览

该产品为筛选大量新药化合物对人造血干祖细胞（HSPC）增殖和往髓系定向分化的影响而设计。

与使用集落形成单位（CFU）实验相比，基于液体培养的HemaTox™实验更加灵活：您可以在整个培养过程的不同时间点添加测试化合物，测定其对更原始或更成熟的祖细胞的影响。HemaTox™髓系试剂盒促进CD34+ HSPC增殖以及分化为表达髓系标志物（如CD13、CD14和CD15）的细胞。

用户可以自选读出方法来量化细胞对每个待测化合物的反应以及估计化合物的IC50和IC90。每套试剂盒可在5块96孔板中测试多达160个条件（三复孔）。该试剂盒可单独使用或与HemaTox™红系试剂盒（产品号 #09701）或HemaTox™巨核细胞试剂盒（产品号 #09707）联合使用，以平行评估谱系特异性药物造血毒性。

实验数据

Figure 1. General HemaTox™ Myeloid Kit Procedure

*The cell isolation step may be omitted if pre-enriched CD34+ cells are used.

Figure 2. Flow Cytometry Plot Showing Cells Produced After Culture of CD34+ HSPCs with the HemaTox™ Myeloid Kit

(A) Human CB CD34+ cells were cultured with the HemaTox™ Myeloid Kit using the protocol as written in the Product Information Sheet (PIS). (B) After the appropriate culture period, cells were harvested and stained for cell surface proteins expressed on myeloid (CD13 and CD15) cells.

Figure 3. Reproducibility of HemaTox™ Myeloid Kit Results Between Experiments and Using Different CD34+ Cell Preparations

(A) Dose-response curves were generated from titrations of 5-FU added to human CB CD34+ cells isolated from 3 donors and cultured with the HemaTox™ Myeloid Kit. Three to five separate experiments were performed with cells from each donor. In each assay similar IC50 values were obtained with cells from different donors and in different experiments with cells from the same donor. Shown are values normalized to the percentages (%) of maximum cell growth without drug. Despite differences in absolute cell counts, curves are reproducible when normalized within each experiment. (B) Table showing IC50 values generated for 5-FU in culture with the myeloid kit including standard deviation (SD) and the coefficient of variation (% CV) across experiments.

Figure 4. Correlation Between IC50 Values for Six Drugs Measured Using the CFU-GM Assay and the 96-Well Plate Liquid Culture-Based HemaTox™ Myeloid Kit

Human BM CD34+ cells were cultured in colony-forming unit - granulocyte/macrophage (CFU-GM) assays with MethoCult™ medium and in liquid culture with the HemaTox™ Myeloid Kit. IC50 values generated using each assay were plotted on the X and Y axes and shown to be highly correlated with a coefficient of determination (R2) of 0.91.

Figure 5. Lineage-Specific Differences in Hematotoxicity Identified with HemaTox™ Erythroid, Myeloid and Megakaryocyte Kits

Results show average IC50 values for each drug tested on human BM CD34+ cells using the HemaTox™ Erythroid (grey), Myeloid (gold) and Megakaryocyte (orange) Kits. Most drugs show similar toxicity for each lineage but some, such as Sunitinib, are ~100-fold more toxic for erythroid than for megakaryocyte progenitor differentiation with intermediate toxicity for myeloid progenitor differentiation. Vertical lines indicate standard error of the mean (SEM) (n = 4 - 8).

产品说明书及文档

请在《产品说明书》中查找相关支持信息和使用说明，或浏览下方更多实验方案。

Document Type

Product Name

Catalog #

Lot #

Language

Document Type

Product Information Sheet

Product Name

HemaTox™ Myeloid Kit

Catalog #

09704

Lot #

All

Language

English

Document Type

Safety Data Sheet 1

Product Name

HemaTox™ Myeloid Kit

Catalog #

09704

Lot #

All

Language

English

Document Type

Safety Data Sheet 2

Product Name

HemaTox™ Myeloid Kit

Catalog #

09704

Lot #

All

Language

English

文献 (1)

Abstract

Bromodomain containing protein 9 (BRD9),a member of the non-canonical BRG1/BRM-associated factor (ncBAF) chromatin remodeling complex,has been implicated as a synthetic lethal target in AML but its function in normal human hematopoiesis is unknown. In hematopoietic stem and progenitor cells (HSPC) genomic or chemical inhibition of BRD9 led to a proliferative disadvantage and loss of stem cells in vitro. Human HSPCs with reduced BRD9 protein levels produced lower numbers of immature mixed multipotent GEMM colonies in semi-solid media. In lineage-promoting culture conditions,cells with reduced BRD9 levels failed to differentiate into the megakaryocytic lineage and showed delayed differentiation into erythroid cells but enhanced terminal myeloid differentiation. HSPCs with BRD9 knock down (KD) had reduced long-term multilineage engraftment in a xenotransplantation assay. An increased number of downregulated genes in RNAseq analysis after BRD9 KD coupled with a gain in chromatin accessibility at the promoters of several repressive transcription factors (TF) suggest that BRD9 functions in the maintenance of active transcription during HSC differentiation. In particular,the hematopoietic master regulator GATA1 was identified as one of the core TFs regulating the gene networks modulated by BRD9 loss in HSPCs. BRD9 inhibition reduced a GATA1-luciferase reporter signal,further suggesting a role for BRD9 in regulating GATA1 activity. BRD9 is therefore an additional example of epigenetic regulation of human hematopoiesis.

View publication

更多信息
物种	人
配方	无血清

更多信息

物种

人

配方

无血清

HemaTox™髓系试剂盒

产品号 #09704

产品号 #（选择产品）

产品号 #09704_C

产品组分包括

总览

实验数据

产品说明书及文档

相关材料与文献

Request Pricing

更多信息

Scientists Helping Scientists™

HemaTox™髓系试剂盒

产品号 #09704

产品号 #（选择产品）

产品号 #09704_C

产品组分包括

总览

实验数据

产品说明书及文档

相关材料与文献

技术资料 (4)

文献 (1)

Abstract

Request Pricing

更多信息

欢迎您关注STEMCELL Technologies的微信公众平台